Business
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs)FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy D
About this update from Terns Pharmaceuticals, Inc.
[{"type":"image","alt":"Terns Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Terns Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c88147929d4056469d083b437f21cbbe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Wrw174RrGmxKRHpik6HSqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/c88147929d4056469d083b437f21cbbe","width":300,"height":61}},"lazy":false},{"type":"text","content":"Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs)","length":243,"tagName":"p"},{"type":"text","content":"FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs.","length":465,"tagName":"p"},{"type":"text","content":"“There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies,” said Scott Harris, chief development and operations officer at Terns. “This designation from the FDA supports the significant potential of TERN-701 to be a best-in-disease therapy for CML patients and offer substantial improvement based on the faster, deeper responses compared to prior TKIs and encouraging safety and tolerability profile observed to date.”","length":487,"tagName":"p"},{"type":"text","content":"“This Breakthrough Therapy Designation, along with the recent agreement for Merck to acquire Terns, has the potential to accelerate efforts to advance TERN-701 to a pivotal trial and to patients,” said Amy Burroughs, chief executive officer of Terns. “This is an exciting time for everyone involved in the TERN-701 program. We are grateful to the investigators, patients and community advocates whose dedication and support have made these advancements possible.”","length":4...